Early graft loss · live donor nephrectomy (primary outcomes)
Summary of findings table ‐ Open showed no clear difference in early graft loss compared with laparoscopic (low certainty).
1 finding from 1 review
Early graft loss ‐ not reported · live donor nephrectomy (primary outcomes)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Early PD catheter function (within 4 weeks of PD catheter insertion) · patients requiring PD catheter placement
1 finding from 1 review
Early PD catheter function (within 4 weeks of PD catheter insertion) · improving catheter function and clinical outcomes in PD patients
It is very uncertain whether percutaneous changes early PD catheter function (within 4 weeks of PD catheter insertion) compared with open surgical PD catheter insertion (very low certainty).
1 finding from 1 review
Early PD catheter function (within 4 weeks of PD catheter insertion) · improving catheter function and clinical outcomes in PD patients
It is very uncertain whether peritoneoscopic changes early PD catheter function (within 4 weeks of PD catheter insertion)… compared with open surgical PD catheter insertion (very low certainty).
1 finding from 1 review
Early PD catheter function (within 4 weeks of PD catheter insertion) · improving catheter function and clinical outcomes in PD patients
Medical showed no clear difference in early PD catheter function (within 4 weeks of PD catheter insertion) compared with open surgical PD catheter insertion (low certainty).
1 finding from 1 review
Early access thrombosis (before 8 weeks) · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents may leads to lower early access thrombosis (before 8 weeks) compared with control (low certainty).
1 finding from 1 review
Early graft thrombosis · kidney transplant recipients
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Death (any cause) · adults with early (stage 1 to 3) non‐diabetic CKD
Angiotensin‐converting enzyme inhibitors showed no clear difference in death (any cause) compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular events · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Kidney failure progression · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CVD events: total (fatal and non‐fatal) · adults with early (stage 1 to 3) non‐diabetic CKD
Angiotensin‐converting enzyme inhibitors showed no clear difference in CVD events: total (fatal and non‐fatal) compared with placebo (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · adults with early (stage 1 to 3) non‐diabetic CKD
Angiotensin‐converting enzyme inhibitors may leads to higher adverse events: number reporting an adverse event compared with placebo (low certainty).
1 finding from 1 review
Kidney failure progression: doubling of SCr (mg/dL) · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · adults with early (stage 1 to 3) non‐diabetic CKD
1 finding from 1 review
Cardiovascular events · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants reporting an adverse event · adults with early (stage 1 to 3) non‐diabetic CKD
It is very uncertain whether angiotensin receptor blockers changes adverse events (number reporting an adverse event) compared with placebo (very low certainty).
1 finding from 1 review
Kidney failure progression: eGFR (mL/min/1.73m²) · adults with early (stage 1 to 3) non‐diabetic CKD
1 finding from 1 review
Death (any cause) · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found